
Sign up to save your podcasts
Or


Kian Sadeghi, founder and CEO of Nucleus Genomics, joins the show to unpack the fall of 23andMe and what its $256M acquisition by Regeneron means for the future of consumer DNA testing.
We talk about what 23andMe got wrong—from its business model to its reliance on outdated genotyping tech—and how a new generation of genomic startups like Nucleus are taking a different approach: full genome sequencing, HIPAA compliance, and consumer empowerment.
We also covered Klarna’s rising credit losses, JPMorgan’s AI-driven hiring slowdown, Waymo’s expansion into San Jose, and Zoox’s new test market in Atlanta.
By Eric Tarczynski5
1616 ratings
Kian Sadeghi, founder and CEO of Nucleus Genomics, joins the show to unpack the fall of 23andMe and what its $256M acquisition by Regeneron means for the future of consumer DNA testing.
We talk about what 23andMe got wrong—from its business model to its reliance on outdated genotyping tech—and how a new generation of genomic startups like Nucleus are taking a different approach: full genome sequencing, HIPAA compliance, and consumer empowerment.
We also covered Klarna’s rising credit losses, JPMorgan’s AI-driven hiring slowdown, Waymo’s expansion into San Jose, and Zoox’s new test market in Atlanta.

16,048 Listeners

1,289 Listeners

544 Listeners

4,353 Listeners

1,982 Listeners

1,094 Listeners

2,371 Listeners

112,193 Listeners

6,089 Listeners

2,671 Listeners

10,189 Listeners

564 Listeners

29,266 Listeners

1,045 Listeners

490 Listeners